Pharma Focus Asia

Nitto Denko Avecia Announces Opening of Manufacturing Expansion in Milford, MA


Nitto Denko Avecia Inc. (Avecia) announced the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, MA.


The opening of the manufacturing facility will take place in 2017 onsite at the Milford, MA facility.

This expansion will help Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned.

It will add 20,000 square feet of manufacturing and office space at Avecia's Milford, MA site and provide CGMP oligonucleotide manufacturing capacity up to 1.8mol.

The total capacity of Avecia's Milford, MA site has now more than doubled up to 3.0mol, which makes Avecia in Milford, MA the largest oligonucleotide manufacturing site in the world.

Avecia engineers have introduced novel technology that executed expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics.

Currently, Avecia has more than 50 open positions at its four locations in MA, OH, and CA. Earlier, it has added more than 120 MA jobs in the last 12 months in Milford, MA.

In addition, the new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering.


NameNitto Denko Avecia Inc. (Avecia)
LocationMilford, MA
Area20,000 Square Feet
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference